$77.95
-0.38%Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Chief Executive Officer, President & Director
Compensation
$1,104,613
Chief Financial Officer & Chief Operating Officer
Compensation
$1,104,613
Co-Founder & Chairman
Compensation
$1,486,468
Co-Founder & Executive Chairman
Compensation
$1,486,468
Executive Vice President, General Counsel & Corporate Secretary
Compensation
$789,513
President, Chief Executive Officer & Director
Compensation
$1,921,774
Senior Vice President & Chief Financial Officer
Senior Vice President of Business Development & Investor Relations
During the last 12 months, insiders have sold $11.69M worth of GMED shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
39.6K
3.69M
-3.7M
-$3.69M
0
0.00
96.0K
8.00M
-8.0M
-$8.00M
0
0.00
0
0.00
+0
+$0
No buying activity
Huller Kelly
Officer: Evp, Gc, Corporate Secretary
$3.44M
Davidar David D
Director
$2.15M
Zarrilli Stephen T
Director
$2.11M
Kline Kyle
Officer: Senior Vice President, Cfo
$2.03M
Rhoads Ann D
Director
$1.40M
Strong bearish signal with $11.69M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
GMED - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | April 21, 2022 | 2022 | |
DEF 14A DEF 14A 2020 N/A | April 22, 2021 | December 31, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | April 23, 2020 | 2020 | |
DEF 14A DEF 14A 2018 N/A | April 25, 2019 | December 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 26, 2018 | December 31, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 27, 2017 | December 31, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.